Jubereq

Denosumab, the active ingredient in Jubereq, is a monoclonal antibody presented as a subcutaneous injection for subcutaneous use. It treats osteoporosis in postmenopausal women, bone loss from glucocorticoid therapy, prevents skeletal‑related events in patients with bone metastases, and is indicated for giant cell tumor of bone. GNH USA supplies Jubereq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jubereq acts on the RANK‑L pathway to reduce pathological bone resorption. - Osteoporosis in postmenopausal women: decreases fracture risk by inhibiting osteoclast activity. - Bone loss associated with glucocorticoid therapy: preserves bone mineral density during long‑term steroid use. - Prevention of skeletal‑related events in patients with bone metastases: reduces incidence of pathologic fractures and spinal cord compression. - Giant cell tumor of bone: limits tumor‑induced bone destruction and recurrence.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema - Low blood calcium (hypocalcemia) - Musculoskeletal pain - Upper respiratory tract infection - Skin rash or itching - Headache

Serious or Rare Side Effects: - Osteonecrosis of the jaw (ONJ) - Atypical femur fracture - Severe hypersensitivity or anaphylaxis - Severe hypocalcemia with seizures or cardiac arrhythmia - Serious infections such as cellulitis or pneumonia

Before initiating therapy, clinicians should assess risk factors and monitor patients closely. - Calcium/Vitamin D supplementation: ensure adequate intake to reduce hypocalcemia risk. - Monitor serum calcium: check levels before each dose, especially in renal impairment. - Dental evaluation: perform oral examination and treat existing infections prior to treatment. - Renal function: adjust monitoring in patients with severe kidney disease. - Hypersensitivity: discontinue if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Denosumab may interact with other agents that affect bone metabolism or immune function.

Major Interactions (Avoid): - Concurrent use of other potent bone resorption inhibitors (e.g., bisphosphonates) may increase risk of severe hypocalcemia. - Live vaccines: administration within 4 weeks of denosumab may reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., corticosteroids, biologics): may heighten infection risk. - Calcium‑containing antacids taken within 4 hours of injection could affect absorption of supplemental calcium. - Concomitant use of strong CYP450 inducers is not expected to alter denosumab levels but clinical monitoring is advised.